Trauma newsround – 28/6/2013
28 June 2013
This week: a new antibiotic for the US military to tackle wound infections, a breakthrough in treating eye injuries, the NFL holds a head injury conference and news of biomarkers to diagnose head injuries.
US military to use new antibiotic drug
The US military is now using a new antibiotic drug to treat personnel who have life-threatening, multidrug resistant bacterial infections. Arbekacin is a new antibiotic treatment for multidrug resistant infections, including Acinetobacter baumannii. Those types of infections may complicate wound healing.
SRMRC is carrying out significant research with a technology called high-throughput DNA sequencing to identify infections such as A. baumannii.
- Click here to read about SRMRC’s work on microbiological research
- Click here to read the full story on the US Army website
US team makes breakthrough on eye injuries
A US company contracted by the Department of Defense has announced new products which can save the vision of people injured in explosive blasts. They have developed a sealant which can be placed in the eye but easily removed by a surgeon before operation, keeping pressure on the wound and fending off infection. Other products include contact lenses infused with medications and a thermos which can keep medical equipment frozen for up to three days in the desert.
SRMRC is currently carrying out research on the effects of traumatic eye injury.
NFL examines risk of asymptomatic head injuries
Even without symptoms, blows to the head can be deceptively severe, neurologists are warning at a meeting on football and brain injury. Experts from Johns Hopkins Medicine, medical representatives from all 32 teams in the National Football League teams and the competition’s commissioner, Roger Goodell, discussed head injuries on Wednesday.
SRMRC is carrying out clinical trials on drugs to treat head injuries, and is also conducting research on different aspects of head injury.
- Click here to read about the SyNAPSe clinical trial
- Click here to read about the Crash-3 clinical trial
- Click here to read about the SRMRC’s research underway into traumatic brain injury
- Click here to read the full story on CNN
Biomarkers can diagnose mild brain injury
Researchers at the Univeristy of Rochester have shown that bloodtests could be used to diagnose mild traumatic brain injury (TBI) and could predict which patients would have abnormalities on head CT.
The research found that two biomarkers could be used for diagnosis, and one of those markers predicted the abonormalities on CT, opening the possibility for reducing the number of scans performed in emergency departments.